<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273452</url>
  </required_header>
  <id_info>
    <org_study_id>Xuehw001</org_study_id>
    <nct_id>NCT03273452</nct_id>
  </id_info>
  <brief_title>Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)</brief_title>
  <acronym>PET</acronym>
  <official_title>Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of PET regimen combined with Chidamide
      for angioimmunoblastic T cell lymphoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in the trial would be given prednisone, etoposide, thalidomide and
      Chidamide, and the response and side effects are observed and documented.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm trial, patients enrolled would be treated in this arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective remission rate(ORR)</measure>
    <time_frame>every 3 months until 24 months after the last patient's enrollment</time_frame>
    <description>the rate of patients who achieve objective remission after the treatment,including CR (complete remission),CRu (complete remission with unrecovered platelet count) and PR (partial remission).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of remission</measure>
    <time_frame>from the day of remission to the date of first documented progression，up to 24 months after the last patient's enrollment</time_frame>
    <description>from date of complete remission to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months after the last patient's enrollment</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>PCT regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically diagnosed as angioimmunoblastic T cell lymphoma (diagnosed by
             pathologic department in IIIA hospitals or verified by certified institutions),
             immunohistochemistry should include: CD3, CD4, CD8, CD20, CD10, CD21, CD35, Bcl6,
             CXCL13, EBER, PD-1, Ki67.

          2. At least on measurable focus (≥1.0*1.0cm by imaging), or at least one evaluable focus;

          3. Age 18—75 years, both male and female;

          4. ECOG 0-2, KPS≥ 70points;

          5. Expected survival ≥3 months;

          6. Peripheral blood neutrophil count ≥1.5×10^9/L, platelet count≥ 75×10^9/L, Hb≥ 90g/L;

          7. Liver function: bilirubin ≤1.5 times of the normal maximum; AST、ALT≤2 times of the
             normal maximum (for patients with liver infiltration AST、ALT≤3 times of the normal
             maximum); renal function: blood creatinine ≤2 times the normal maximum;

          8. Negative random pregnancy test for fertile women patients within 7 days before
             enrollment;

          9. No radiation therapy, chemotherapy, targeted therapy nor hemopoietic stem cell
             transplantation within 4 weeks before enrollment;

         10. No anti-tumor therapy at enrollment, including herbal therapy, immunotherapy and
             biologic therapy, symptomatic treatment is not within this range;

        Exclusion Criteria:

          1. Women during pregnancy or lactation, and fertile women that are not willing to take
             contraceptive measurements;

          2. Patients with other malignant tumors simultaneously that have not been effectively
             controlled;

          3. Patients with history of using HDAC inhibitors;

          4. Patients who are allergic to medicine used in the trial, or have metabolic disorders
             toward these medicine;

          5. Patients with severe active infection;

          6. Patients with HIV or syphilis infection;

          7. Patients with prolonged QT interval (male &gt; 450ms，female &gt; 470ms), or chronic heart
             failure patients with level III or IV cardiac function; or those have the following
             heart disease within 6 months before enrollment: acute coronary syndrome, acute heart
             failure (heart function level III or IV), distinctive ventricular arrhythmias
             (prolonged ventricular tachycardia, ventricular fibrillation, etc);

          8. Patients with history of organ transplantation;

          9. Patients with history of thrombosis and embolism;

         10. Patients with mental disorders or those who are unable to sign a written consent;

         11. Patients with drug abuse or long-time alcoholism that may influence the result of the
             trial;

         12. Patients who do not have capacity of legal transactions;

         13. Patients currently in other clinical trials;

         14. Those who are recognized as inappropriate for the trial by the investigators;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongwei Xue, MD. PhD</last_name>
    <phone>(+86)13475875599</phone>
    <email>Xuehongwei1867@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwei Xue, MD. PhD</last_name>
      <phone>(+86)13475875599</phone>
      <email>Xuehongwei1867@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao University</investigator_affiliation>
    <investigator_full_name>Hongwei Xue</investigator_full_name>
    <investigator_title>MD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the trial is finished, all the data would be available at the principle investigator's location.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

